A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder

Desvenlafaxine 200 and 400 mg/day resulted in greater improvement on the Hamilton Rating Scale for Depression compared to placebo.

• Both doses of desvenlafaxine showed greater efficacy than placebo on multiple depression rating scales.
• Desvenlafaxine 200 mg/day was significantly more effective than placebo in achieving remission and reducing pain intensity.
• Desvenlafaxine 400 mg/day demonstrated improved outcomes in specific pain intensity measures compared to placebo.
• Most adverse events reported were mild or moderate, with few significant changes noted in vital signs and lab tests.
• The findings support the potential efficacy and safety of desvenlafaxine for treating major depressive disorder.

AI simplified